论文部分内容阅读
来自于欧洲的研究人员在近期的《新英格兰医学杂志》(NEJM)上刊文指出,肺癌细胞中的一种蛋白的存在或缺乏能够帮助医生预测化疗是否有助于延长患者手术后的生存时间。该项研究有助于医生在开始治疗前确定哪些患者可获益于一种类型的化疗。美国疾病预防与控制中心(CDC)研究中心的Eddie Reed在附随的一篇评论中对此解释说,研究结果提示临床拥有一种可鉴别患者能否从基于铂类的化疗中获益的手段。法国Gusatve Roussy研究所的合作者Jean-Charles So-ria博士认为,理论上,该研究发现可应用于其它肿瘤类型,尽管尚未得以证实。ERCC1蛋白(其重要作用是修复DNA)水平未检出的志愿者当使用基于铂类的化疗药物(如顺铂)时,其5年生存率可达到47%;手术切除肿瘤后未治疗者的生存率降至39%,当肿瘤含有丰富的ERCC1蛋白时,结果正好相反,那些未接受任何化疗的患者要好于经治疗者;未治疗的患者的生存率
Researchers from Europe recently published in the New England Journal of Medicine (NEJM) pointed out that the presence or absence of a protein in lung cancer cells can help doctors predict whether chemotherapy will help patients to prolong survival after surgery. . The study helps doctors determine which patients can benefit from one type of chemotherapy before starting treatment. Eddie Reed of the Centers for Disease Control and Prevention (CDC) Research Center explained in an accompanying commentary that the findings suggest that the clinic has a means of identifying patients who can benefit from platinum-based chemotherapy. Dr. Jean-Charles So-ria, a collaborator of the Gusatve Roussy Institute in France, believes that, theoretically, the study can be applied to other tumor types, although it has not yet been confirmed. Volunteers with undetected levels of ERCC1 protein (which plays an important role in repairing DNA) have a 5-year survival rate of 47% when using platinum-based chemotherapeutics (such as cisplatin); untreated patients after surgical resection of tumors The survival rate was reduced to 39%. When the tumors contained abundant ERCC1 protein, the results were the opposite. Those who did not receive any chemotherapy were better than those who were treated; the survival rate of untreated patients.